Gastrointestinal tract injury Associated with Aspirin and Other Drugs: Data Mining of the FDA Adverse Event Reporting System, FAERS
10.11256/jjdi.15.147
- VernacularTitle:米国有害事象自発報告（FAERS）を用いたアスピリンおよび併用薬の消化管傷害に関する解析
- Author:
Kouichi Hosomi
;
Mai Fujimoto
;
Hiroko Hachiken
;
Keita Sumitoko
;
Mitsutaka Takada
- Publication Type:Journal Article
- Keywords:
adverse event;
angiotensin II receptor blocker;
aspirin;
FAERS;
gastrointestinal tract injury
- From:Japanese Journal of Drug Informatics
2014;15(4):147-154
- CountryJapan
- Language:English
-
Abstract:
Objective: To examine the signal of gastrointestinal tract injury induced by aspirin and other drugs, we analyzed the US FDA Adverse Event Reporting System (FAERS).
Methods: After deleting duplicate submissions, we analyzed the reports involving gastrointestinal tract injury associated with aspirin, H2-receptor antagonists (H2RAs), proton pump inhibitors (PPIs), ACE inhibitors, angiotensin II receptor blockers (ARBs), and antiplatelet and antithrombotic drugs. The reporting odds ratio (ROR), a recognized pharmacovigilance tool, was used for the quantitative detection of signals.
Results: Based on 29,017,485 co-occurrences, i.e., drug-adverse event pairs, found in 1,645,605 reports from 2004 to 2009, the ROR-associated gastrointestinal tract injury for aspirin alone, aspirin with H2RAs, aspirin with PPIs, aspirin with ACE inhibitors, aspirin with ARBs, and aspirin with antiplatelet and antithrombotic drugs were 2.88, 1.42, 1.46, 1.00, 1.05, and 2.98-8.26, respectively. The following summarizes the types of listed reports: 86 reports described the daily aspirin doses, and 36/86 were between 75 and 100 mg; 343 reports described the periods between the start-date for aspirin and the date when gastrointestinal tract injury occurred, of which 128/343 were within one month while 215/343 were over one month; additionally, 78 reports described the total cumulative doses of aspirin, and 17/78 were between 1 and 5 g.
Conclusion: The data suggest that H2RAs, PPIs, ACE inhibitors, and ARBs may reduce gastrointestinal tract injury associated with aspirin in possibility.
